Oxolife, backed by Inveready,CDTI and BStartup, receives a 2.4M€ grant to develop a new treatment for infertility related to polycystic ovarian sindrom

13/12/2022 Nota de prensa OXOLIFE, BACKED BY INVEREADY,CDTI AND BSTARTUP, RECEIVES A 2.4M€ GRANT TO DEVELOP A NEW TREATMENT FOR INFERTILITY RELATED TO POLYCYSTIC OVARIAN SINDROM Oxolife, the Women’s Reproductive Health R&D biotech, has been awarded with a 2.4M€ grant from the Spanish Science and Innovation Ministry (Plan Estatal de Investigación Científica) to develop a…